Healthcare / Drug Manufacturers - Specialty & GenericBuenos Aires
$166.00
-0.50 (-0.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $397.8M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
574.6%
↑Gross Margin
-9.4%
↓Debt/Equity
-1.81
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.4%
FCF CAGR
+77.8%
FCF margin
6.2%
FCF / Net income
-0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.40B · net income $-4.60B · FCF $397.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.40B | $6.40B | $10.89B | $9.86B | $4.28B |
| Net Income | $-4.60B | $-4.60B | $-1.86B | $1.23B | $-25.2M |
| EBITDA | $-2.65B | $-2.65B | $-1.02B | $2.48B | $732.7M |
| EPS | -107.95 | -107.95 | -43.78 | 28.78 | -0.59 |
| Gross Margin | -9.4% | -9.4% | 46.3% | 29.5% | 46.8% |
| Operating Margin | -49.1% | -49.1% | 23.5% | 1.5% | 20.5% |
| Net Margin | -71.8% | -71.8% | -17.1% | 12.4% | -0.6% |
| Balance Sheet | |||||
| Debt/Equity | -1.81 | -1.81 | 0.61 | 0.54 | 0.95 |
| Current Ratio | 0.87 | 0.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $397.8M | $397.8M | $706.7M | $215.9M | $70.7M |
| Returns | |||||
| ROE | 574.6% | 574.6% | -49.9% | 29.4% | -2.2% |
| Valuation | |||||
| P/E | — | — | — | 2.24 | — |
| EV/EBITDA | — | — | — | 1.68 | 1.73 |
| P/B | — | — | 1.32 | 0.66 | 0.47 |
| Growth & Yield | |||||
| Revenue Growth | -41.2% | -41.2% | 10.4% | 130.6% | — |
| EPS Growth | -146.6% | -146.6% | -252.1% | 4961.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+76.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-43.78 → -107.95
Residual
+76.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.